Beth Woods
Senior Research Fellow

Profile

Biography

Beth is a Senior Research Fellow in the Team for Economic Evaluation and Health Technology Assessment (TEEHTA). Prior to joining CHE Beth was a Director in the Health Economics team at Oxford Outcomes, a private consulting firm, where she specialised in applied economic evaluation from 2006-2013. During this time Beth contributed to numerous submissions to the National Institute for Health and Care Excellence (NICE) and other national HTA agencies. Beth holds a BA in Economics from the University of Cambridge and an MSc in Economic Evaluation in Healthcare from City University.

Beth’s research interests include the application of statistical and decision analysis methods to health technology assessment.

Research

Research group(s)

• Economic evaluation of health technologies

External activities

Invited talks and conferences

• Quigley JM, Woods B, Thompson J, Bryden PA, Scott DA. Confronting heterogeneity: using systematic review effectively for meta-analysis. International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 16th Annual European Conference. 2013 November 2-6; Dublin, Ireland.
• Dewilde S, Woods B, Castaigne JG, Parker C, Dunlop W. Cost-effectiveness of bendamustine-rituximab in first-line indolent NHL: a patient-level simulation. International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 16th Annual European Conference. 2013 November 2-6; Dublin, Ireland.
• Thompson J, Barcena L, Woods B, Lui Y, Huang H, Hatton C. Comparing brentuximab vedotin overall survival data against published outcome data in patients with relapsed/refractory Hodgkin lymphoma post-autologous stem cell transplantation (ASCT). Proceedings of the 17^th Congress of the European Haematology Association (EHA); 2012 June 14-17; Amsterdam, Netherlands.
• Woods B, Thompson J, Barcena L, Liu Y, Huang H, Martinez C. Comparing brentuximab vedotin overall survival data to standard of care in patients with relapsed/refractory Hodgkin lymphoma (HL) post-autologous stem cell transplant (ASCT). Proceedings of the International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 15^th Annual European Conference; 2012 November 3-7; Berlin, Germany.
• Woods B, Jensen J, Morris J, Punekar Y, Davies A, Hawkins N. Cost-effectiveness of biological therapy in the UK for the treatment of rheumatoid arthritis following exposure to a previous tumour necrosis factor alpha inhibitor: a patient level simulation model. Proceedings of the European League Against Rheumatism (EULAR) Annual European Congress of Rheumatology; 2010 June 16-19; Rome, Italy.
• Woods B, Hawkins N. Use of pharmacogenetic testing to determine adjuvant hormonal therapy choice in early stage breast cancer patients: a value of information analysis. Proceedings of the International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 14^th Annual International Meeting; 2009 May 16-20; Florida, U.S.
• Hawkins N, Scott D, Woods B, Thatcher N. Time to broaden our horizons: the case for network meta-analysis within relapsed non-small cell lung cancer (NSCLC). Proceedings of the 33^rd meeting of the European Society for Medical Oncology (ESMO); 2008 September 12-16; Stockholm, Sweden.